These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

559 related articles for article (PubMed ID: 19420940)

  • 1. Rapid progression from mild cognitive impairment to Alzheimer's disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE epsilon4/epsilon4 genotype.
    Blom ES; Giedraitis V; Zetterberg H; Fukumoto H; Blennow K; Hyman BT; Irizarry MC; Wahlund LO; Lannfelt L; Ingelsson M
    Dement Geriatr Cogn Disord; 2009; 27(5):458-64. PubMed ID: 19420940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
    JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma apolipoprotein E levels in longitudinally followed patients with mild cognitive impairment and Alzheimer's disease.
    Giannisis A; Al-Grety A; Carlsson H; Patra K; Twohig D; Sando SB; Lauridsen C; Berge G; Grøntvedt GR; Bråthen G; White LR; Kultima K; Nielsen HM
    Alzheimers Res Ther; 2022 Aug; 14(1):115. PubMed ID: 36002891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sex differences in CSF biomarkers vary by Alzheimer disease stage and
    Babapour Mofrad R; Tijms BM; Scheltens P; Barkhof F; van der Flier WM; Sikkes SAM; Teunissen CE
    Neurology; 2020 Oct; 95(17):e2378-e2388. PubMed ID: 32788242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progression from MCI to AD: predictive value of CSF Aβ42 is modified by APOE genotype.
    Kester MI; Verwey NA; van Elk EJ; Blankenstein MA; Scheltens P; van der Flier WM
    Neurobiol Aging; 2011 Aug; 32(8):1372-8. PubMed ID: 19748159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genome-wide association reveals genetic effects on human Aβ42 and τ protein levels in cerebrospinal fluids: a case control study.
    Han MR; Schellenberg GD; Wang LS;
    BMC Neurol; 2010 Oct; 10():90. PubMed ID: 20932310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progression to dementia in memory clinic patients with mild cognitive impairment and normal β-amyloid.
    Rosenberg A; Solomon A; Jelic V; Hagman G; Bogdanovic N; Kivipelto M
    Alzheimers Res Ther; 2019 Dec; 11(1):99. PubMed ID: 31805990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CSF Abeta42, Tau and phosphorylated Tau, APOE epsilon4 allele and MCI type in progressive MCI.
    Herukka SK; Helisalmi S; Hallikainen M; Tervo S; Soininen H; Pirttilä T
    Neurobiol Aging; 2007 Apr; 28(4):507-14. PubMed ID: 16546302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
    Sunderland T; Mirza N; Putnam KT; Linker G; Bhupali D; Durham R; Soares H; Kimmel L; Friedman D; Bergeson J; Csako G; Levy JA; Bartko JJ; Cohen RM
    Biol Psychiatry; 2004 Nov; 56(9):670-6. PubMed ID: 15522251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease.
    van Rossum IA; Visser PJ; Knol DL; van der Flier WM; Teunissen CE; Barkhof F; Blankenstein MA; Scheltens P
    J Alzheimers Dis; 2012; 29(2):319-27. PubMed ID: 22233766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between Cerebrospinal Fluid Biomarkers for Alzheimer's Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease.
    Mandecka M; Budziszewska M; Barczak A; Pepłońska B; Chodakowska-Żebrowska M; Filipek-Gliszczyńska A; Nesteruk M; Styczyńska M; Barcikowska M; Gabryelewicz T
    J Alzheimers Dis; 2016 Jul; 54(1):157-68. PubMed ID: 27472875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of oxidative stress and inflammatory metabolites with Alzheimer's disease cerebrospinal fluid biomarkers in mild cognitive impairment.
    Ahmad S; Yang W; Orellana A; Frölich L; de Rojas I; Cano A; Boada M; Hernández I; Hausner L; Harms AC; Bakker MHM; Cabrera-Socorro A; Amin N; Ramírez A; Ruiz A; Van Duijn CM; Hankemeier T
    Alzheimers Res Ther; 2024 Jul; 16(1):171. PubMed ID: 39080778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. APOE ε4 is associated with higher levels of CSF SNAP-25 in prodromal Alzheimer's disease.
    Wang S; Zhang J; Pan T;
    Neurosci Lett; 2018 Oct; 685():109-113. PubMed ID: 30144541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple Effect of APOE Genotype on Clinical and Neuroimaging Biomarkers Across Alzheimer's Disease Spectrum.
    Liu Y; Tan L; Wang HF; Liu Y; Hao XK; Tan CC; Jiang T; Liu B; Zhang DQ; Yu JT;
    Mol Neurobiol; 2016 Sep; 53(7):4539-47. PubMed ID: 26298664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Don't forget about tau: the effects of ApoE4 genotype on Alzheimer's disease cerebrospinal fluid biomarkers in subjects with mild cognitive impairment-data from the Dementia Competence Network.
    Benson GS; Bauer C; Hausner L; Couturier S; Lewczuk P; Peters O; Hüll M; Jahn H; Jessen F; Pantel J; Teipel SJ; Wagner M; Schuchhardt J; Wiltfang J; Kornhuber J; Frölich L
    J Neural Transm (Vienna); 2022 Jun; 129(5-6):477-486. PubMed ID: 35061102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. APOE ε4 moderates abnormal CSF-abeta-42 levels, while neurocognitive impairment is associated with abnormal CSF tau levels in HIV+ individuals - a cross-sectional observational study.
    Cysique LA; Hewitt T; Croitoru-Lamoury J; Taddei K; Martins RN; Chew CS; Davies NN; Price P; Brew BJ
    BMC Neurol; 2015 Apr; 15():51. PubMed ID: 25880550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile: a longitudinal MRI study.
    Tosun D; Schuff N; Truran-Sacrey D; Shaw LM; Trojanowski JQ; Aisen P; Peterson R; Weiner MW;
    Neurobiol Aging; 2010 Aug; 31(8):1340-54. PubMed ID: 20570401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discordant amyloid-β PET and CSF biomarkers and its clinical consequences.
    de Wilde A; Reimand J; Teunissen CE; Zwan M; Windhorst AD; Boellaard R; van der Flier WM; Scheltens P; van Berckel BNM; Bouwman F; Ossenkoppele R
    Alzheimers Res Ther; 2019 Sep; 11(1):78. PubMed ID: 31511058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apolipoprotein E epsilon4 does not modulate amyloid-β-associated neurodegeneration in preclinical Alzheimer disease.
    Desikan RS; McEvoy LK; Holland D; Thompson WK; Brewer JB; Aisen PS; Andreassen OA; Hyman BT; Sperling RA; Dale AM;
    AJNR Am J Neuroradiol; 2013 Mar; 34(3):505-10. PubMed ID: 22976236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of Apolipoprotein E ε4 in Early and Late Mild Cognitive Impairment.
    Luo Y; Tan L; Therriault J; Zhang H; Gao Y;
    Eur Neurol; 2021; 84(6):472-480. PubMed ID: 34340229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.